TY - JOUR AU - Kovács, Levente AU - Ferenci, Tamás AU - Gombos, Balázs AU - Füredi, András AU - Rudas, Imre AU - Szakács, Gergely AU - Drexler, Dániel András TI - Positive Impulsive Control of Tumor Therapy—A Cyber-Medical Approach JF - IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS: SYSTEMS J2 - IIEEE TRANS SYST MAN CYBERN SYST VL - 54 PY - 2023 IS - 1 SP - 597 EP - 608 PG - 12 SN - 2168-2216 DO - 10.1109/TSMC.2023.3315637 UR - https://m2.mtmt.hu/api/publication/34168948 ID - 34168948 LA - English DB - MTMT ER - TY - JOUR AU - Szebényi, Kornélia AU - Füredi, András AU - Bajtai, Eszter AU - Sama, Sai Nagender AU - Csiszar, Agnes AU - Gombos, Balázs AU - Szabó, Pál Tamás AU - Grusch, Michael AU - Szakács, Gergely TI - Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells JF - DRUG RESISTANCE UPDATES J2 - DRUG RESIST UPDATE VL - 71 PY - 2023 PG - 12 SN - 1368-7646 DO - 10.1016/j.drup.2023.101007 UR - https://m2.mtmt.hu/api/publication/34163799 ID - 34163799 LA - English DB - MTMT ER - TY - CHAP AU - Gergics, Borbála AU - Vajda, Flóra AU - Puskás, Melánia AU - Füredi, András AU - Drexler, Dániel András TI - Mathematical modeling of phototoxicity during fluorescent imaging of tumor spheroids T2 - IEEE 27th International Conference on Intelligent Engineering Systems 2023 (INES 2023) PB - IEEE Hungary Section CY - Budapest SN - 9798350328516 PY - 2023 SP - 291 EP - 296 PG - 6 DO - 10.1109/INES59282.2023.10297657 UR - https://m2.mtmt.hu/api/publication/34081684 ID - 34081684 LA - English DB - MTMT ER - TY - CHAP AU - Puskás, Melánia AU - Gergics, Borbála AU - Gombos, Balázs AU - Füredi, András AU - Szakács, Gergely AU - Kovács, Levente AU - Drexler, Dániel András TI - Noise modeling of tumor size measurements from animal experiments for virtual patient generation T2 - IEEE 27th International Conference on Intelligent Engineering Systems 2023 (INES 2023) PB - IEEE Hungary Section CY - Budapest SN - 9798350328516 PY - 2023 SP - 53 EP - 60 PG - 8 DO - 10.1109/INES59282.2023.10297747 UR - https://m2.mtmt.hu/api/publication/34081565 ID - 34081565 LA - English DB - MTMT ER - TY - JOUR AU - Vajda, Flóra AU - Szepesi, Áron AU - Várady, György AU - Sessler, Judit AU - Kiss, Dániel AU - Erdei, Zsuzsa AU - Szebényi, Kornélia AU - Nemet, Katalin AU - Szakács, Gergely AU - Füredi, András TI - Comparison of Different Clinical Chemotherapeutical Agents' Toxicity and Cell Response on Mesenchymal Stem Cells and Cancer Cells JF - CELLS J2 - CELLS-BASEL VL - 11 PY - 2022 IS - 19 PG - 14 SN - 2073-4409 DO - 10.3390/cells11192942 UR - https://m2.mtmt.hu/api/publication/33183423 ID - 33183423 N1 - Institute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary Doctoral School of Molecular Medicine, Semmelweis University, Budapest, 1089, Hungary Creative Cell Kft., Budapest, 1119, Hungary Software Engineering Institute, John von Neumann Faculty of Informatics, Óbuda University, Budapest, 1034, Hungary National Laboratory for Drug Research and Development, Budapest, 1117, Hungary Export Date: 15 June 2023 Correspondence Address: Füredi, A.; Institute of Enzymology, Hungary; email: furedi.andras@ttk.hu Chemicals/CAS: bendamustine, 16506-27-7, 3543-75-7; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; doxorubicin, 23214-92-8, 25316-40-9; irinotecan, 100286-90-6, 97682-44-5; methotrexate, 15475-56-6, 59-05-2, 7413-34-5, 7532-09-4, 6745-93-3, 51865-79-3, 60388-53-6; mitoxantrone, 65271-80-9, 70476-82-3; rebemadlin, 548472-68-0, 675576-97-3, 675576-98-4; vinblastine, 865-21-4; DNA, 9007-49-2; Antineoplastic Agents; DNA Tradenames: 3984, Tocris, United Kingdom; ab 252173, ABCR, Germany; hy 13780, MedChemexpress, United States; m 9929, Sigma Aldrich, United States; nutlin 3, Tocris, United Kingdom; p 4413, Tocris, United Kingdom; vnr 461201, Accord Healthcare, United KingdomEnspire (microplate reader), Perkin Elmer, United States; JuLI Manufacturers: ABCR, Germany; Accord Healthcare, United Kingdom; Tocris, United Kingdom; MedChemexpress, United States; Sigma Aldrich, United StatesCell Signaling Technology, United States; Perkin Elmer, United States Funding details: 2969-1-KÖ-39-2020 Funding details: International Brain Research Organization, IBRO Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, 2019-1.3.1-KK-2019-00007, GINOP-2.1.7-15, K-128011, RRF-2.3.1-21-2022-00015 Funding text 1: This research was funded by the Hungarian National Research, Development and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015 to G.S. and A.F., 2019-1.3.1-KK-2019-00007 to G.S. and A.F., NKFIH K-128011 to G.V., GINOP-2.1.7-15 (Stem Tox) to K.N.), the International Brain Research Organization (IBRO Return Home Fellowship to K.S.) and by the collaboration between the Research Centre for Natural Sciences of the Eötvös Loránd Research Network and the Szentágothai Research Centre of the University of Pécs on internationally recognized medical research projects (2969-1-KÖ-39-2020) to A.F. AB - Mesenchymal stem cells (MSCs) or fibroblasts are one of the most abundant cell types in the tumor microenvironment (TME) exerting various anti- and pro-apoptotic effects during tumorigenesis, invasion, and drug treatment. Despite the recently discovered importance of MSCs in tumor progression and therapy, the response of these cells to chemotherapeutics compared to cancer cells is rarely investigated. A widely accepted view is that these naive MSCs have higher drug tolerance than cancer cells due to a significantly lower proliferation rate. Here, we examine the differences and similarities in the sensitivity of MSCs and cancer cells to nine diverse chemotherapy agents and show that, although MSCs have a slower cell cycle, these cells are still sensitive to various drugs. Surprisingly, MSCs showed similar sensitivity to a panel of compounds, however, suffered fewer DNA double-stranded breaks, did not enter into a senescent state, and was virtually incapable of apoptosis. Our results suggest that MSCs and cancer cells have different cell fates after drug treatment, and this could influence therapy outcome. These findings could help design drug combinations targeting both MSCs and cancer cells in the TME. LA - English DB - MTMT ER - TY - CHAP AU - Gergics, Borbála AU - Gombos, Balázs AU - Vajda, Flóra AU - Füredi, András AU - Gergely, Szakács AU - Drexler, Dániel András TI - Pharmacodynamics modeling based on in vitro 2D cell culture experiments T2 - 2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC) PB - IEEE CY - Piscataway (NJ) SN - 9781665452588 PY - 2022 SP - 2409 EP - 2414 PG - 6 DO - 10.1109/SMC53654.2022.9945355 UR - https://m2.mtmt.hu/api/publication/33138330 ID - 33138330 LA - English DB - MTMT ER - TY - PAT AU - Mező, Gábor AU - Hegedüs, Kristóf AU - Kiss, Krisztina AU - SZAKÁCS, GERGELY AU - Füredi, András AU - VARGA, ZOLTÁN AU - TÓTH, SZILÁRD AU - BARTA, GERGŐ AU - NAGYNÉ, NASZÁLYI LÍVIA AU - GAÁL, ANIKÓ TI - NOVEL ANTICANCER THERAPY PY - 2022 UR - https://m2.mtmt.hu/api/publication/33111421 ID - 33111421 AB - The invention relates to the field of cancer therapy. In particular, a highly effective chemotherapy is provided in the form of liposome-encapsulated 2-deamino-2-pyrrolino-daunorubicin, which has been found to eliminate cancer cells and to support overall survival without causing severe undesired effects in mouse models of different types of cancer. LA - English DB - MTMT ER - TY - JOUR AU - Dékay, Valéria AU - Karai, Edina AU - Füredi, András AU - Szebényi, Kornélia AU - Szakács, Gergely AU - Vajdovich, Péter TI - P-Glycoprotein Activity at Diagnosis Does Not Predict Therapy Outcome and Survival in Canine B-Cell Lymphoma JF - CANCERS J2 - CANCERS VL - 14 PY - 2022 IS - 16 PG - 17 SN - 2072-6694 DO - 10.3390/cancers14163919 UR - https://m2.mtmt.hu/api/publication/33070122 ID - 33070122 N1 - Innovációs szolgáltató bázis létrehozásadiagnosztikai, terápiás és kutatási célú kiberorvosiren...(2019-1-3-1-KK-2019-00007) Támogató: NKFIH AB - Various mechanisms are known to be involved in the development of multidrug resistance during cancer treatment. P-glycoprotein (P-gp) decreases the intracellular concentrations of cytotoxic drugs by an energy-dependent efflux mechanism. The aim of this study was to investigate the predictive value of P-gp function based on the evaluation of P-gp activity in tumor cells obtained from canine B-cell lymphoma patients at diagnosis. P-gp function of 79 immunophenotyped canine lymphoma samples was determined by flow cytometry using the Calcein assay. Dogs were treated with either the CHOP or the L-CHOP protocol, a subset of relapsed patients received L-asparaginase and lomustine rescue treatments. Among the 79 dogs, the median overall survival time was 417 days, and the median relapse-free period was 301 days. 47 percent of the samples showed high P-gp activity, which was significantly higher in Stage IV cancer patients compared to Stage II + III and V. Whereas staging was associated with major differences in survival times, we found that the intrinsic P-gp activity of tumor cells measured at diagnosis is not predictive for therapy outcome. Further studies are needed to identify the intrinsic and acquired resistant mechanisms that shape therapy response and survival in B-cell canine lymphoma patients. LA - English DB - MTMT ER - TY - CHAP AU - Nagy , Erzsébet AU - Czakó, Bence Géza AU - Siket, Máté AU - Gombos, Balázs AU - Füredi, András AU - Szakács, Gergely AU - Kovács, Levente AU - Drexler, Dániel András ED - Szakál, Anikó TI - Tracking parameter changes of an Impulsive Tumor Growth Model T2 - IEEE 10th Jubilee International Conference on Computational Cybernetics and Cyber-Medical Systems ICCC 2022 PB - IEEE Hungary Section CY - Budapest SN - 9781665481762 PY - 2022 SP - 179 EP - 184 PG - 6 DO - 10.1109/ICCC202255925.2022.9922736 UR - https://m2.mtmt.hu/api/publication/33060653 ID - 33060653 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Levente AU - Czakó, Bence Géza AU - Siket, Máté AU - Ferenci, Tamás AU - Füredi, András AU - Gombos, Balázs AU - Szakács, Gergely AU - Drexler, Dániel András TI - Experimental Closed-Loop Control of Breast Cancer in Mice JF - COMPLEXITY J2 - COMPLEXITY VL - 2022 PY - 2022 PG - 10 SN - 1076-2787 DO - 10.1155/2022/9348166 UR - https://m2.mtmt.hu/api/publication/32838813 ID - 32838813 N1 - Physiological Controls Research Center, Research and Innovation Center of Óbuda University, Óbuda University, Budapest, Hungary Institute for Computer Science and Control (SZTAKI), Eötvös Loránd Research Network (ELKH), Budapest, Hungary Drug Resistance Research Group, Research Center for Natural Sciences, Eötvös Loránd Research Network (ELKH), Budapest, Hungary Semmelweis University, Molecular Medicine PhD School, Budapest, Hungary Institute of Cancer Research, Medical University of Vienna, Vienna, Austria Export Date: 13 September 2022 Correspondence Address: Czakó, B.; Physiological Controls Research Center, Hungary; email: czakesz@gmail.com Funding details: European Research Council, ERC Funding details: Horizon 2020, 2019-1.3.1-KK-2019-00007, 679681 Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA, ELKH KO-40/2020 Funding details: Innovációs és Technológiai Minisztérium Funding text 1: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Program (grant agreement no. 679681). Project no. 2019-1.3.1-KK-2019-00007 has been implemented with the support provided from the National Research, Development, and Innovation Fund of Hungary, financed under the 2019-1.3.1-KK funding scheme. Bence Czako and Mate Siket were supported by the UNKP-20-3 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development, and Innovation Fund and the Eotvos Lorand Research Network Secretariat under grant agreement no. ELKH KO-40/2020 (Development of cybermedical systems based on AI and hybrid cloud methods). The current work was also supported by the Collaboration between the Research Centre for Natural Sciences of the Eotvos Lorand Research Network and the Szentagothai Research Centre of University of Pecs on internationally recognized medical research projects LA - English DB - MTMT ER -